CT45A1 and neoplasm: Endogenous CT45A1High MSS/MSI‐H tumor organoids could be used in future studies to explore the molecular function of CT45A1 through a loss‐of‐function approach along with autologous or allogenic NK cells to optimize the treatment regimen.